All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
Introducing
Now you can personalise
your ALL Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from Servier. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Bookmark this article
The two most common malignancies in children are B-cell precursor and T-cell precursor acute lymphoblastic leukemia (B-ALL, T-ALL). Although genetic variations can be used to classify ALL, these are numerous and heterogenous. The 2016 revision to the World Health Organization (WHO) classification of ALL, added new provisional entities: BCR-ABL1-like (or Ph-like) ALL, iAMP21 (intrachromosomal amplification of chromosome 21), and early T-cell precursor ALL (ETP-ALL).1 In addition to somatic mutations, the WHO classification also included genes that are associated with predisposition to myeloid neoplasms including CEBPA, DDX41, RUNX1, ANKRD26, ETV6, and GATA2. There are also several syndromes that increase susceptibility to ALL including Li Fraumeni (TP53), and Wiskott Aldrich syndrome (WAS). Some genes (PAX5, ETV6, TP53, and IKZF1) associated with ALL are found to have both germline and somatic mutations, thus increasing the susceptibility to ALL. The ALL Hub has previously published an article describing the different genes impacted by germline mutations.
In a recently published study by Shin et al., the association of genetic alterations and predisposition to ALL in both pediatric and adult patients was investigated.1 The key findings are summarized below.
The study investigated genetic alterations in Korean patients with ALL using targeted gene panel sequencing.
Paired initial diagnosis and complete remission (CR) bone marrow samples from patients with ALL were selected.
Bone marrow slides of when the patients were in CR were used to detect germline mutations. Nearly a third of the patients had received allogeneic stem cell transplantation (allo-SCT), and in these patients, CR status bone marrow slides before transplantation were used to detect germline mutations. Slides with no apparent residual leukemic cells were used as control samples.
A gene panel consisting of 81 genes, known to be associated with 23 predisposition syndromes, was investigated. In addition to sequence variants, gene-level copy number variations (CNVs) were investigated.
In total, 65 pediatric (<20 years) and 28 adult patients with ALL were included. Patient characteristics are summarized in Table 1. The most common type of B-ALL in adults was BCR-ABL1, whereas in children was B-ALL not otherwise specified (NOS) and B-ALL with hyperdiploidy.
Table 1. Patient characteristics*
Characteristic |
Children |
Adults |
---|---|---|
Sex, n |
||
Male |
35 |
10 |
Female |
30 |
18 |
Diagnosis, n |
||
B-ALL, NOS |
25 |
8 |
B-ALL with t(9;22)(q34.1;q11.2); BCR-ABL1 |
2 |
11 |
B-ALL with t(v;11q23.3); KMT2A rearranged |
4 |
1 |
B-ALL with t(12;21)(p13.2; q22.1); ETV6-RUNX1 |
9 |
0 |
B-ALL with hyperdiploidy |
16 |
1 |
B-ALL with t(1;19)(q23; p13.3); TCF3-PBX1 |
2 |
2 |
T-ALL |
5 |
5 |
Early T-cell precursor acute leukemia |
2 |
0 |
B-ALL cytogenic risk group, n |
||
Good |
26 |
2 |
Intermediate |
26 |
9 |
High |
6 |
12 |
B-ALL, B-cell acute lymphoblastic leukemia; NOS, not otherwise specified; T-ALL, T-cell acute lymphoblastic leukemia. |
Only one pathogenic TP53 variant (Accession: NM_000546.5) was identified in an adult patient with B-ALL NOS. A known CNV, CASP10 (Accession: NM_032977.3), was identified in one pediatric patient with B-ALL NOS.
Five heterozygous autosomal recessive (AR) primary immunodeficiency disorder (PID)-associated gene variants were identified in five other patients (as shown in Table 2).
Table 2. Germline sequence variants*
Patient ID |
Age/Sex |
Gene |
% variant |
Syndrome |
---|---|---|---|---|
ALL0009 |
51/F |
TP53 |
40.3 |
Li-Fraumeni syndrome |
ALL0067 |
18/M |
CASP10 |
— |
Autoimmune lymphoproliferative syndrome, Type II |
ALL0077 |
10/M |
TYK2 |
40.2 |
Immunodeficiency 35, AR |
ALL0053 |
2/M |
IL12RB1 |
50.7 |
Immunodeficiency 30, AR |
ALL0060 |
40/M |
LPIN2 |
44.0 |
Majeed syndrome, AR |
ALL0071 |
2/F |
CTC1 |
47.0 |
Dyskeratosis congenital, AR |
ALL0021 |
2/M |
LIG4 |
42.6 |
LIG4 syndrome, AR |
AR, autosomal recessive; F, female; M, male. |
A total of 197 somatic sequence variants and 223 somatic CNV were identified. The most common somatic sequence variants and CNVs in B-ALL and T-ALL patients are shown in Table 3. All NRAS and KRAS variants were previously reported variants. The majority of the FLT3 variants were known variants in hematological malignancies, and about 50% of the PAX5 variants were also recurrent variants.
Table 3. Somatic sequence variants*
Sequence variant |
% |
---|---|
Somatic sequence variant in T-ALL |
|
NOTCH1 |
50 |
FBXW7 |
25 |
IL7R |
25 |
NRAS |
25 |
DNMT3A |
17 |
PHF6 |
17 |
GATA3 |
17 |
Somatic sequence variant in B-ALL |
|
NRAS |
17 |
FLT3 |
14 |
KRAS |
9 |
SETD2 |
7 |
PAX5 |
6 |
CREBBP |
6 |
CNV in T-ALL |
|
CDKN2A/B |
50 |
CRLF2 |
17 |
GATA3 |
8 |
CSF2RA |
8 |
BCOR |
8 |
CNV in B-ALL |
|
CDKN2A/B |
31 |
IKZF1 |
16 |
ETV6 |
12 |
ERG |
12 |
RB1 |
11 |
B-ALL, B-cell acute lymphoblastic leukemia; CNV, copy number variations; T-ALL, T-cell acute lymphoblastic leukemia. |
IKZF1 alterations were present in 15 B-ALL patients:
The study found recurrent somatic alterations in Korean T-ALL patients, consistent with previous studies. IKZF1 alteration was associated with an adverse effect on OS and RFS in childhood ALL. Six patients had variants in six genes associated with PID. Of the 81 genes associated with 23 predisposition syndromes, only one predisposition germline mutation (TP53) was identified. Taken together, the results indicate a low probability of germline mutation predisposition to ALL in Korean patients. However, the study was limited by the number of patients with early T-cell precursor ALL, and further studies should explore this patient group.
Your opinion matters
Subscribe to get the best content related to ALL delivered to your inbox